Literature DB >> 15494526

Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2.

Amato de Paulis1, Nunzia Montuori, Nella Prevete, Isabella Fiorentino, Francesca Wanda Rossi, Valeria Visconte, Guido Rossi, Gianni Marone, Pia Ragno.   

Abstract

Basophils circulate in the blood and are able to migrate into tissues at sites of inflammation. Urokinase plasminogen activator (uPA) binds a specific high affinity surface receptor (uPAR). The uPA-uPAR system is crucial for cell adhesion and migration, and tissue repair. We have investigated the presence and function of the uPA-uPAR system in human basophils. The expression of uPAR was found at both mRNA and protein levels. The receptor was expressed on the cell surface of basophils, in the intact and cleaved forms. Basophils did not express uPA at either the protein or mRNA level. uPA (10(-12)-10(-9) M) and its uPAR-binding N-terminal fragment (ATF) were potent chemoattractants for basophils, but did not induce histamine or cytokine release. Inactivation of uPA enzymatic activity by di-isopropyl fluorophosphate did not affect its chemotactic activity. A polyclonal Ab against uPAR inhibited uPA-dependent basophil chemotaxis. The uPAR-derived peptide 84-95 (uPAR84-95) induced basophil chemotaxis. Basophils expressed mRNA for the formyl peptide receptors formyl peptide receptor (FPR), FPR-like 1 (FPRL1), and FPRL2. The FPR antagonist cyclosporin H prevented chemotaxis induced by FMLP, but not that induced by uPA and uPAR84-95. Incubation of basophils with low and high concentrations of FMLP, which desensitize FPR and FPRL1, respectively, but not FPRL2, slightly reduced the chemotactic response to uPA and uPAR84-95. In contrast, desensitization with WKYMVm, which also binds FPRL2, markedly inhibited the response to both molecules. Thus, uPA is a potent chemoattractant for basophils that seems to act through exposure of the chemotactic uPAR epitope uPAR84-95, which is an endogenous ligand for FPRL2 and FPRL1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15494526     DOI: 10.4049/jimmunol.173.9.5739

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Structural basis of interaction between urokinase-type plasminogen activator and its receptor.

Authors:  Cyril Barinka; Graham Parry; Jennifer Callahan; David E Shaw; Alice Kuo; Khalil Bdeir; Douglas B Cines; Andrew Mazar; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2006-08-26       Impact factor: 5.469

2.  The cross-talk between the urokinase receptor and fMLP receptors regulates the activity of the CXCR4 chemokine receptor.

Authors:  Nunzia Montuori; Katia Bifulco; Maria Vincenza Carriero; Claudio La Penna; Valeria Visconte; Daniela Alfano; Ada Pesapane; Francesca Wanda Rossi; Salvatore Salzano; Guido Rossi; Pia Ragno
Journal:  Cell Mol Life Sci       Date:  2010-10-24       Impact factor: 9.261

3.  Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1.

Authors:  Lea M Beaulieu; Frank C Church
Journal:  Exp Cell Res       Date:  2006-12-14       Impact factor: 3.905

4.  The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis.

Authors:  N Prevete; F Liotti; C Visciano; G Marone; R M Melillo; A de Paulis
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

5.  Adaptive evolution of formyl peptide receptors in mammals.

Authors:  Yoshinori Muto; Stéphane Guindon; Toshiaki Umemura; László Kőhidai; Hiroshi Ueda
Journal:  J Mol Evol       Date:  2015-01-28       Impact factor: 2.395

6.  Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists.

Authors:  Agostino Cilibrizzi; Igor A Schepetkin; Gianluca Bartolucci; Letizia Crocetti; Vittorio Dal Piaz; Maria Paola Giovannoni; Alessia Graziano; Liliya N Kirpotina; Mark T Quinn; Claudia Vergelli
Journal:  Bioorg Med Chem       Date:  2012-04-27       Impact factor: 3.641

Review 7.  Regulation of cell signalling by uPAR.

Authors:  Harvey W Smith; Chris J Marshall
Journal:  Nat Rev Mol Cell Biol       Date:  2010-01       Impact factor: 94.444

Review 8.  Role of mesenchymal stem cell-derived fibrinolytic factor in tissue regeneration and cancer progression.

Authors:  Beate Heissig; Douaa Dhahri; Salita Eiamboonsert; Yousef Salama; Hiroshi Shimazu; Shinya Munakata; Koichi Hattori
Journal:  Cell Mol Life Sci       Date:  2015-09-09       Impact factor: 9.261

Review 9.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

10.  Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.

Authors:  Maria Paola Giovannoni; Igor A Schepetkin; Agostino Cilibrizzi; Letizia Crocetti; Andrei I Khlebnikov; Claes Dahlgren; Alessia Graziano; Vittorio Dal Piaz; Liliya N Kirpotina; Serena Zerbinati; Claudia Vergelli; Mark T Quinn
Journal:  Eur J Med Chem       Date:  2013-04-08       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.